Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

TD Cowen analyst Yaron Werber initiated coverage of Forte Biosciences (FBRX) with a Buy rating and no price target The firm says FB102 is a ...

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

NDAQ:TLSA) Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it often struggles to mount an effective response. Recent research, published ...

to investigate whether the generation of inducible Foxp3-expressing regulatory T cells (Treg) might constitute additional mechanisms underlying the immunosuppressive properties of MMF. The animals ...

Activating agents enable the efficient preparation of organozinc complexes from zinc metal and organohalides, but their mechanisms had been obscured by the heterogeneous nature of these systems.

while sometimes an "abiding expression of faith," is also a culturally conditioned survival mechanism. For "people at the margins," she writes, extending "forgiveness" is sometimes a necessary ...